Approximately 40 percent of human breast tumors depend on estrogens for proliferation [1], and are therefore treated with drugs such as antiestrogens and aromatase inhibitors, which target the estrogen receptor (ER) [2]. Here, ESR1 is linked to breast neoplasm.